A biotechnology company developing biologics for chronic, underserved conditions in pets.
Market:
Cats represent over 370 million pets globally. There are currently not many approved biologics for major feline conditions. Yuyu Bio aims to lead this untapped market by developing species-specific therapeutics.
Technology:
Yuyu Bio is pioneering biologics tailored to feline immunology, targeting chronic diseases with no approved biologic options. Our lead molecules are engineered to maximize safety, duration of action, and owner compliance.
Advantages:
- Species-specific protein design
- Injectable dosing
- First-in-class therapeutic targets
- Improved safety and compliance
Development Stage:
- Pre-clinical
Patents Issued:
- Filings in preparation.
Contact:
Email: robert@yuyubio.com
Portfolio Companies
- Anaco
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- Diatom Biolab
- Eximius Diagnostics
- Giant BioSystems
- Hikari Medical Technologies
- ImmunoVec
- MedStat AI Inc.
- Mervyn's Petcare, Inc.
- Meteor Biotech, LLC
- My Block Skin, Inc.
- Nanomega CryoAI
- NEXT-TFX, Inc.
- Paralos Bioscience Inc.
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Prosper DNA
- Protean Research, Inc.
- Purpose Bio
- RaizDx
- RiboForge
- Saku Biosciences, Inc.
- SolGrapH, Inc.
- Sorriso Pharmaceuticals
- Thermeutics, Inc.
- Vault Pharma
- Veergen, Inc.
- Yuyu Bio, Inc.